Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

The Effect of Acupuncture on Brain-Derived Exosomal Load, Cognitive Function, and Sleep Disturbances in Patients With Fibromyalgia.

16 november 2026 bijgewerkt door: Vardakis Panagiotis, University of Crete

The Effect of Pain Treatment on Brain-Derived Exosomal Load, Cognitive Function, and Sleep Disturbances in Patients With Fibromyalgia: A Pilot, Prospective, Controlled, Observational Trial

The goal of this observational study is to learn about the effects of electroacupuncture on exosome load and clinical outcomes in patients with fibromyalgia, a chronic condition characterized by widespread pain, fatigue, sleep disturbances, and cognitive dysfunction.

The main questions it aims to answer are:

  1. Does acupuncture alter the load of circulating exosomes in patients with fibromyalgia?
  2. Is a change in exosome load associated with improvements in pain, cognitive function, and sleep quality?
  3. Can exosome load serve as a potential biomarker of brain-related changes in conditions involving chronic pain?

Participants with fibromyalgia receiving electroacupuncture as part of their routine clinical care will provide blood samples before and after treatment for exosome analysis. Participants will also undergo assessments of mechanical pain threshold, pain intensity, overall symptom burden, cognitive function (using objective neuropsychological tests and self-report questionnaires), and sleep quality. Healthy volunteers will be included as a comparison group.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Chronic pain has emerged as a major public health challenge, affecting millions of individuals worldwide and imposing a substantial socioeconomic burden. Beyond physical suffering, chronic pain is increasingly recognized as a condition associated with cognitive impairment, including deficits in memory, attention, executive function, and information processing.

According to the neural resource theory, persistent pain continuously consumes cognitive resources, thereby reducing the brain's ability to perform higher cognitive tasks. However, several additional mechanisms have been proposed, including neuroplastic alterations, neuroinflammation mediated by microglial activation, psychosocial factors, and disturbances of the gut-brain axis.

Recent advances in extracellular vesicle biology have highlighted the importance of exosomes as mediators of intercellular communication. Brain-derived exosomes are capable of crossing the blood-brain barrier and carry proteins, lipids, messenger RNAs, microRNAs, and other molecular cargo reflecting ongoing pathological processes within the central nervous system. Emerging evidence suggests altered exosomal microRNA profiles in fibromyalgia patients, while other studies have demonstrated associations between exosome-related biomarkers and neurodegenerative processes, cognitive decline, and sleep disorders. Nevertheless, review of the literature suggests that no study has comprehensively investigated the relationship between exosomal alterations, cognitive dysfunction, sleep disturbances, and response to electroacupuncture in fibromyalgia.

Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive dysfunction. Cognitive symptoms, often described as "fibro fog," significantly impair daily functioning and quality of life. Despite increasing recognition of these manifestations, the biological mechanisms linking chronic pain to cognitive impairment remain poorly understood. Fibromyalgia represents an ideal clinical model for investigating these interactions because it combines chronic widespread pain with pronounced cognitive dysfunction and sleep disturbances. Previous studies have demonstrated alterations in functional brain networks, inflammatory pathways, and neuroendocrine regulation in patients with fibromyalgia.

The overall objective of this study is to investigate whether brain-derived exosomes can serve as biomarkers of pain-related cognitive dysfunction and sleep disturbances in patients with fibromyalgia and whether their profile is modified following pain treatment.

The specific objectives are:

  1. To compare brain-derived exosomal load between patients with fibromyalgia and healthy controls.
  2. To evaluate the effects of electroacupuncture on exosomal load and composition.
  3. To assess the relationship between exosomal load and clinical outcomes, including pain severity, symptom burden, cognitive performance, and sleep quality.
  4. To explore whether changes in exosomal load correlate with treatment-induced clinical improvement.

Studietype

Observationeel

Inschrijving (Geschat)

30

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Crete
      • Heraklion, Crete, Griekenland, 71110
        • Medical School, University of Crete

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 70 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Participants that are included in the Fibromyalgia Cohort, are patients with widespread musculoskeletal pain, who are referred to Chronic Pain Clinic of University hospital of Heraklion from Rheumatologists, after excluding other rheumatologist diseases and confirming the diagnosis of Fibromyalgia. They will be enrolled in the study if only they meet inclusion criteria and they do not meet exclusion criteria Participants in the Healthy Cohort, are healthy volunteers, that meet inclusion criteria of the study.

Beschrijving

Inclusion Criteria:

Inclusion Criteria for the Healthy Cohort

Participants will be eligible for inclusion in the Healthy Cohort group if they meet all of the following criteria:

  1. Age between 18 and 70 years.
  2. Absence of any chronic pain condition or other medical disorder known to affect systemic inflammatory burden during the study period.
  3. Absence of cognitive impairment, as assessed by the Montreal Cognitive Assessment (MoCA) and the Trail Making Test (TMT) Parts A and B. The criterion for the absence of cognitive impairment, as assessed by the Montreal Cognitive Assessment (MoCA), is a score of 26 or higher (≥26), as recommended in the literature.
  4. Absence of poor sleep quality, defined according to the Pittsburgh Sleep Quality Index (PSQI).
  5. No history of depression or other neuropsychiatric disorders. If healthy volunteers are found to have depression or any other neuropsychiatric disorder, they will be immediately referred for psychiatric and psychological assessment.
  6. No use of antidepressant medications or sleep-promoting agents, including herbal or over-the-counter sleep aids.

Inclusion Criteria for the Fibromyalgia Cohort

Participants will be eligible for inclusion in the fibromyalgia group if they meet all of the follow-ing criteria:

  1. Diagnosis of fibromyalgia established by a rheumatologist according to the American College of Rheumatology (ACR) 2010 classification criteria.
  2. Age between 18 and 70 years.
  3. Moderate-to-severe pain intensity, defined as a Visual Analogue Scale (VAS) score ≥ 4/10.
  4. Presence of cognitive difficulties documented through the Montreal Cognitive Assess-ment (MoCA) and the Trail Making Test (TMT) Parts A and B. The criterion for the presence of cognitive impairment, as assessed by the Montreal Cognitive Assessment (MoCA), is a score below 26.
  5. Poor sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≥ 5.

Exclusion Criteria:

Exclusion Criteria for the Fibromyalgia Group

Participants meeting any of the following criteria will be excluded from the study:

  1. Coexisting neurological disorders associated with cognitive impairment, including dementia.
  2. Coexisting psychiatric disorders known to affect cognitive function, including major depressive disorder, bipolar disorder, or schizophrenia. Major depression will be defined as a Patient Health Questionnaire-9 (PHQ-9) score ≥ 20.
  3. Presence of medical conditions associated with altered inflammatory burden, including rheumatologic diseases.
  4. Use of sleep medications that cannot be safely discontinued prior to study participation.
  5. Antidepressant treatment that cannot either be discontinued or maintained at a stable dosage for at least three months before treatment initiation and throughout the entire study period.

5. Severe cognitive impairment resulting in an inability to understand the Participant Information Sheet and provide informed consent, as assessed by the Montreal Cognitive Assessment (MoCA). Patients with a score below 18/30 will be excluded from the study and referred to the appropriate healthcare professional for further assessment and management.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: CASE_CONTROL
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Fibromyalgia cohort

Patients diagnosed with Fibromyalgia

**Electroacupuncture Intervention**

Participants in this group will receive electroacupuncture treatment for 24 weeks. During the first 6 weeks, treatment sessions will be administered twice weekly. Thereafter, participants will receive maintenance treatments every two weeks until completion of the 24-week intervention period.

A standardized electroacupuncture protocol will be applied using the following acupuncture points:

  • GV20 (Baihui)
  • EX-HN3 (Yintang)
  • BL10 (Tianzhu)
  • GB21 (Jianjing)
  • BL60 (Kunlun)
  • ST36 (Zusanli)
  • LV3 (Taichong)
  • SP6 (Sanyinjiao)
  • LI4 (Hegu)
  • LI11 (Quchi)
  • KI3 (Taixi)
  • CV6 (Qihai)
  • CV12 (Zhongwan)
  • HT7 (Shenmen) Additional individualized points will be used if required.

Sterile, single-use disposable needles will be inserted at the specified acupoints. Electrical stimulation will be applied according to the study protocol.

Healthy cohort

Healthy volunteers, age, sex and education level matched to Fibromyalgia cohort

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Brain-derived exosomes - Changes in exosomal load
Tijdsspanne: In the Fibromyalgia Cohort this outcome will be assessed before treatment, at 6 weeks, and at 6 months after treatment initiation. In the Healthy Cohort this outcome will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

Changes in exosomal cargo, exosomal protein expression and molecular signatures relevant to neuroinflammation, neuronal dysfunction, and neurodegeneration will be analyzed by comprehensive proteomic profiling of exosomes (label-free, non-targeted proteomics). This outcome will be assessed in both Cohorts of the study.

In the Fibromyalgia Cohort this outcome will be assessed before treatment, at 6 weeks, and at 6 months after treatment initiation. In the Healthy Cohort this outcome will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Objective Cognitive Assessment - Greek version of the Trail Making Test (TMT) Part A
Tijdsspanne: For participants belonging to the Fibromyalgia Cohort, scores will be assessed Before treatment (baseline), at 6 weeks, and at 6 months. In the Healthy Cohort, scores will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

Objective changes in cognitive function from treatment will be assessed using the Greek version of the Trail Making Test (TMT) Part A. Raw scores will be converted to age-, sex-, and education-adjusted z-scores using Greek normative data to facilitate comparisons between groups. This outcome will be assessed in both groups.

For participants belonging to the Fibromyalgia Cohort, scores will be assessed Before treatment (baseline), at 6 weeks, and at 6 months. In the Healthy Cohort, scores will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.
Objective Cognitive Assessment - Greek version of the Trail Making Test (TMT) Part B
Tijdsspanne: For participants in the Fibromyalgia Cohort, scores will be assessed Before treatment (baseline), at 6 weeks, and at 6 months. In the Healthy Cohort, scores will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

Objective changes in cognitive function from treatment will be assessed using the Greek version of the Trail Making Test (TMT) Part B. Raw scores will be converted to age-, sex-, and education-adjusted z-scores using Greek normative data to facilitate comparisons between groups. This outcome will be assessed in both groups.

For participants in the Fibromyalgia Cohort, scores will be assessed Before treatment (baseline), at 6 weeks, and at 6 months. In the Healthy Cohort, scores will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.
Pain Assessment - BPI Short Form questionnaire - Change of Pain Interference score
Tijdsspanne: Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

Pain's impact on participants' daily functioning will be assessed using the Brief Pain Inventory (BPI) Short form questionnaire. The Pain Interference score will be calculated by adding the scores from Items 9A-9G and divided by 7. This outcome will be assessed only in Fibromyalgia Cohort.

Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.
Pain Assessment - BPI Short Form questionnaire - Change of Pain severity score
Tijdsspanne: Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

Pain intensity will be assessed using the Brief Pain Inventory (BPI) Short Form questionnaire. The Pain severity score will be calculated by adding the scores from Items 3-6 and divided by 4. This outcome will be assessed only in Fibromyalgia Cohort.

Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.
Pain Assessment - BPI Short Form questionnaire - Change of percentage relief from treatment
Tijdsspanne: Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

Pain relief from treatment will be assessed using the Brief Pain Inventory (BPI) Short Form questionnaire. The Pain relief from treatment will be assessed by Items 8 of questionnaire. This outcome will be assessed only in Fibromyalgia Cohort.

Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.
Pain Assessment - Algometer - Change of Mechanical threshold of Pain
Tijdsspanne: Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

Mechanical threshold of participants' pain in Fibromyalgia Cohort will be assessed using the Algometer. By the algometer pressure will be applied to two-four painful points and the patients will indicate by pressing a button the pressure that provokes pain. This outcome will be assessed only in Fibromyalgia Cohort.

Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.
Objective Cognitive Assessment - Greek version of Montreal Cognitive Assessment Test (MoCA)
Tijdsspanne: For participants in the Fibromyalgia Cohort, scores will be assessed before treatment (baseline), at 6 weeks, and at 6 months. Scores in the Healthy Cohort will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment in study.

Objective changes in cognitive function from treatment will be assessed using the Greek Version of Montreal Cognitive Assessment Test (MoCA) . Scores will result from summing the scores from the individual tests of MOCA as indicated from the authors. This outcome will be assessed in both groups.

For participants in the Fibromyalgia Cohort, scores will be assessed before treatment (baseline), at 6 weeks, and at 6 months. Scores in the Healthy Cohort will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment in study.
Sleep Disturbances - Pittsburgh Sleep Quality Index (PSQI)
Tijdsspanne: The scores will be assessed in both cohorts before enrollment in the study, at 6 weeks and 6 months after enrollment.

Sleep quality changes will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated instrument for the evaluation of subjective sleep quality and sleep-related disturbances. It groups 19 self-rated questions into 7 component scores, each graded on a scale of 0 to 3. The global score ranges from 0 to 21 and a global score greater than 5 indicates poor sleep quality.

The scores will be assessed in both cohorts before enrollment in the study, at 6 weeks and 6 months after enrollment.
Subjective Cognitive Assessment - Revised Fibromyalgia Impact Questionnaire (FIQ-R) - Changes in cognitive function
Tijdsspanne: Scores will be assessed only in the Fibromyalgia Cohort before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation, because participants in Healthy Cohort do not experience pain.

Changes in cognitive function will be assessed using the cognitive subscale of the Revised Fibromyalgia Impact Questionnaire (FIQ-R), which evaluates patients' self-perceived cognitive difficulties. In this sub scale the patient is asked to rate the severity of specific cognitive issues over the past 7 days on a 0-10 numeric scale. This outcome will be assessed only in Fibromyalgia Cohort.

Scores will be assessed only in the Fibromyalgia Cohort before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation, because participants in Healthy Cohort do not experience pain.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 november 2026

Primaire voltooiing (Geschat)

1 november 2028

Studie voltooiing (Geschat)

1 november 2028

Studieregistratiedata

Eerst ingediend

16 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

16 november 2026

Eerst geplaatst (Werkelijk)

20 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 november 2026

Laatste update ingediend die voldeed aan QC-criteria

16 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren